Pacira Pharmaceuticals Stock Price, News & Analysis (NASDAQ:PCRX)

$30.15 -5.95 (-16.48 %)
(As of 02/19/2018 12:18 PM ET)
Previous Close$36.10
Today's Range$29.35 - $32.00
52-Week Range$29.35 - $58.95
Volume3.92 million shs
Average Volume1.11 million shs
Market Capitalization$1.22 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.88

About Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals logoPacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA). DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis.

Receive PCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:PCRX
CUSIP69512710
Phone973-254-3560

Debt

Debt-to-Equity Ratio1.03%
Current Ratio6.99%
Quick Ratio6.24%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$276.37 million
Price / Sales4.43
Cash Flow$0.31 per share
Price / Cash98.81
Book Value$5.85 per share
Price / Book5.15

Profitability

Trailing EPS($1.31)
Net Income$-37,940,000.00
Net Margins-18.25%
Return on Equity-13.77%
Return on Assets-6.34%

Miscellaneous

Employees503
Outstanding Shares40,570,000

Pacira Pharmaceuticals (NASDAQ:PCRX) Frequently Asked Questions

What is Pacira Pharmaceuticals' stock symbol?

Pacira Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCRX."

How were Pacira Pharmaceuticals' earnings last quarter?

Pacira Pharmaceuticals Inc (NASDAQ:PCRX) released its quarterly earnings results on Wednesday, November, 8th. The company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.15. The business had revenue of $67.30 million for the quarter, compared to analysts' expectations of $68.99 million. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The company's revenue was down 1.6% compared to the same quarter last year. During the same period last year, the business earned $0.20 EPS. View Pacira Pharmaceuticals' Earnings History.

When will Pacira Pharmaceuticals make its next earnings announcement?

Pacira Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Pacira Pharmaceuticals.

Where is Pacira Pharmaceuticals' stock going? Where will Pacira Pharmaceuticals' stock price be in 2018?

19 Wall Street analysts have issued 1-year price objectives for Pacira Pharmaceuticals' stock. Their predictions range from $27.00 to $80.00. On average, they anticipate Pacira Pharmaceuticals' stock price to reach $46.81 in the next twelve months. View Analyst Ratings for Pacira Pharmaceuticals.

What are Wall Street analysts saying about Pacira Pharmaceuticals stock?

Here are some recent quotes from research analysts about Pacira Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Pacira’s top line mainly comprises contribution from its marketed product. The company is heavily dependent on Exparel for growth, which accounts for a significant chunk of its revenues. The company discontinued DepoCyt(e) in June 2017 due to persistent technical issues and lower collaborative licensing and milestone revenues. However, during the third quarter of 2017, the FDA accepted the resubmission of Pacira's supplemental new drug application (sNDA) seeking expansion of Exparel label to include administration via nerve block for prolonged regional analgesia and set an action date of Apr 6, 2018. Additionally, Pacira remains optimistic of its partnership with J&J to market and promote the use of Exparel, with their sales and medical education teams. Loss estimates have narrowed ahead of the Q4 earnings." (1/9/2018)
  • 2. Canaccord Genuity analysts commented, "We’re looking for more than two months of data showing solid growth before we become positive on the potential for a meaningful inflection in Exparel use trends, especially with a noisy October that may have benefited from hurricane-related deferred procedures that negatively impacted September volumes. We remain HOLD rated on PCRX shares." (12/29/2017)
  • 3. Cowen Inc analysts commented, "Nerve block data for Exparel is anticipated within the next month, and our consultants." (7/14/2017)
  • 4. Mizuho analysts commented, "We continue to like PCRX for the 2017 potential catalyst flow (ahead of the nerve block data), growth opportunities from increased DePuy Synthes (DPS) orthopedic promotion, and a reasonable takeout thesis. We updated our share count and interest expense following the recent convertible debt refinancing, and included the latest Feb data from Symphony. While we are comfortable with the growth rates we estimate for the 20 mL vial, we need to monitor our expectations for the smaller 10 mL vial that launched this year and is not yet reported by Symphony. Our estimates came down slightly due to lowered expectations on this 10 mL vial and we lower our PT to $54 from $59 due to additional share count dilution and increase in net debt." (3/23/2017)

Who are some of Pacira Pharmaceuticals' key competitors?

Who are Pacira Pharmaceuticals' key executives?

Pacira Pharmaceuticals' management team includes the folowing people:

  • David M. Stack, Chairman of the Board, Chief Executive Officer (Age 66)
  • Charles A. Reinhart III, Chief Financial Officer (Age 56)
  • Scott N. Braunstein M.D., Chief Operating Officer (Age 53)
  • James B. Jones M.D., Senior Vice President, Chief Medical Officer (Age 52)
  • Kristen Marie Williams, Chief Administrative Officer, General Counsel, Secretary (Age 43)
  • Richard Scranton M.D., Chief Scientific Officer
  • Robert J. Weiland, Chief Commercial Officer (Age 57)
  • Mark Froimson, Director
  • Gary Pace Ph.D., Director (Age 69)
  • Laura A. Brege, Independent Director (Age 59)

Who owns Pacira Pharmaceuticals stock?

Pacira Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.12%), HealthCor Management L.P. (6.90%), Consonance Capital Management LP (3.95%), Macquarie Group Ltd. (3.12%), Rock Springs Capital Management LP (2.73%) and Stephens Investment Management Group LLC (2.51%). Company insiders that own Pacira Pharmaceuticals stock include David M Stack, James B Jones, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Paul J Hastings and Scott Braunstein. View Institutional Ownership Trends for Pacira Pharmaceuticals.

Who sold Pacira Pharmaceuticals stock? Who is selling Pacira Pharmaceuticals stock?

Pacira Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Teachers Advisors LLC, Cornerstone Capital Management Holdings LLC., Peregrine Capital Management LLC, Aristeia Capital LLC, BlackRock Inc., Guggenheim Capital LLC, Metropolitan Life Insurance Co. NY and Bank of New York Mellon Corp. Company insiders that have sold Pacira Pharmaceuticals company stock in the last year include David M Stack, James B Jones, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings and Scott Braunstein. View Insider Buying and Selling for Pacira Pharmaceuticals.

Who bought Pacira Pharmaceuticals stock? Who is buying Pacira Pharmaceuticals stock?

Pacira Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Consonance Capital Management LP, HealthCor Management L.P., Two Sigma Advisers LP, Renaissance Technologies LLC, Element Capital Management LLC, Macquarie Group Ltd. and Two Sigma Investments LP. Company insiders that have bought Pacira Pharmaceuticals stock in the last two years include Mark A Kronenfeld and Mark Froimson. View Insider Buying and Selling for Pacira Pharmaceuticals.

How do I buy Pacira Pharmaceuticals stock?

Shares of Pacira Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pacira Pharmaceuticals' stock price today?

One share of Pacira Pharmaceuticals stock can currently be purchased for approximately $30.15.

How big of a company is Pacira Pharmaceuticals?

Pacira Pharmaceuticals has a market capitalization of $1.22 billion and generates $276.37 million in revenue each year. The company earns $-37,940,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Pacira Pharmaceuticals employs 503 workers across the globe.

How can I contact Pacira Pharmaceuticals?

Pacira Pharmaceuticals' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]


MarketBeat Community Rating for Pacira Pharmaceuticals (PCRX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  551 (Vote Outperform)
Underperform Votes:  306 (Vote Underperform)
Total Votes:  857
MarketBeat's community ratings are surveys of what our community members think about Pacira Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pacira Pharmaceuticals (NASDAQ:PCRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.372.472.472.60
Ratings Breakdown: 1 Sell Rating(s)
10 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $46.81$49.50$49.77$54.50
Price Target Upside: 29.67% upside26.60% upside23.65% upside52.02% upside

Pacira Pharmaceuticals (NASDAQ:PCRX) Consensus Price Target History

Price Target History for Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals (NASDAQ:PCRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2018Needham & Company LLCDowngradeBuy -> Hold$55.00HighView Rating Details
2/16/2018BarclaysReiterated RatingBuy$40.00HighView Rating Details
2/16/2018Canaccord GenuityReiterated RatingHold$32.00HighView Rating Details
2/15/2018BMO Capital MarketsLower Price TargetMarket Perform$41.00 -> $32.00HighView Rating Details
2/15/2018OppenheimerReiterated RatingHoldHighView Rating Details
2/13/2018Piper Jaffray CompaniesSet Price TargetBuy$49.00LowView Rating Details
1/19/2018Seaport Global SecuritiesInitiated CoverageBuy -> Buy$50.00LowView Rating Details
1/5/2018WedbushReiterated RatingBuyLowView Rating Details
1/4/2018HC WainwrightSet Price TargetBuy -> Buy$52.00 -> $55.00LowView Rating Details
1/4/2018JPMorgan Chase & Co.Reiterated RatingHoldLowView Rating Details
1/4/2018Royal Bank of CanadaSet Price TargetBuy$54.00HighView Rating Details
1/2/2018Leerink SwannInitiated CoverageMkt Perform -> Market Perform$46.00LowView Rating Details
11/29/2017MizuhoDowngradeBuy -> Neutral$53.00 -> $44.00MediumView Rating Details
11/16/2017Janney Montgomery ScottSet Price TargetSell$27.00N/AView Rating Details
11/9/2017Jefferies GroupLower Price TargetBuy$52.00N/AView Rating Details
10/4/2017Bank of AmericaLower Price TargetBuy$46.00 -> $45.00LowView Rating Details
9/28/2017Goldman Sachs GroupInitiated CoverageNeutral -> Neutral$41.00MediumView Rating Details
9/7/2017CIBCInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
8/2/2017CowenReiterated RatingHoldMediumView Rating Details
10/7/2016Brean CapitalInitiated CoverageHoldN/AView Rating Details
2/28/2016NomuraReiterated RatingBuy$100.00N/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Pacira Pharmaceuticals (NASDAQ:PCRX) Earnings History and Estimates Chart

Earnings by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals (NASDAQ PCRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018$0.11N/AView Earnings Details
11/8/2017Q3 2017($0.04)$0.11$68.99 million$67.30 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.05)($0.11)$73.37 million$70.90 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.23)($0.19)$70.30 million$69.30 millionViewListenView Earnings Details
3/1/2017Q416$0.01$0.09$73.08 million$72.90 millionViewListenView Earnings Details
11/2/2016Q316($0.02)$0.20$67.16 million$68.40 millionViewListenView Earnings Details
8/4/2016Q216$0.03$0.19$67.80 million$69.60 millionViewListenView Earnings Details
5/2/2016Q116$0.07$0.15$67.11 million$65.50 millionViewListenView Earnings Details
2/25/2016Q415$0.27$0.20$68.40 million$69.30 millionViewListenView Earnings Details
10/27/2015Q315$0.15$0.10$60.44 million$62.20 millionViewListenView Earnings Details
7/30/2015Q215$0.04$0.20$62.97 million$59.10 millionViewListenView Earnings Details
4/30/2015Q115$0.02$0.05$61.11 million$58.30 millionViewListenView Earnings Details
2/24/2015Q4$0.27$0.35$61.62 million$61.80 millionViewListenView Earnings Details
10/30/2014Q314$0.10$0.14$52.20 million$52.00 millionViewListenView Earnings Details
7/31/2014Q214($0.21)$0.04$42.20 million$47.20 millionViewListenView Earnings Details
5/1/2014Q1($0.32)($0.19)$35.40 million$36.70 millionViewListenView Earnings Details
2/25/2014Q4($0.31)($0.33)ViewListenView Earnings Details
10/31/2013Q313($0.35)($0.30)$22.10 million$23.30 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.43)($0.42)ViewN/AView Earnings Details
5/8/2013Q1 2013($0.49)($0.61)ViewN/AView Earnings Details
3/7/2013Q4 2012($0.41)($0.50)ViewN/AView Earnings Details
11/1/2012Q312($0.44)($0.49)$7.85 million$8.50 millionViewN/AView Earnings Details
8/9/2012Q2 2012($0.43)($0.27)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.39)($0.47)ViewN/AView Earnings Details
3/27/2012Q4 2011($0.54)($0.58)ViewN/AView Earnings Details
10/31/2011Q3 2011($0.59)($0.55)ViewN/AView Earnings Details
8/11/2011Q2 2011($0.58)($0.51)ViewN/AView Earnings Details
5/11/2011Q1 2011($0.53)($0.98)ViewN/AView Earnings Details
3/31/2011Q4 2010($11.95)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Pacira Pharmaceuticals (NASDAQ:PCRX) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.86 EPS
Next Year EPS Consensus Estimate: $-0.23 EPS

Dividends

Dividend History for Pacira Pharmaceuticals (NASDAQ:PCRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Pacira Pharmaceuticals (NASDAQ PCRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.60%
Insider Trades by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)
Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals (NASDAQ PCRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/10/2018David M. StackCEOSell28,885$40.19$1,160,888.15View SEC Filing  
12/15/2017Lauren Bullaro RikerVPSell340$43.70$14,858.00View SEC Filing  
11/20/2017James B. JonesSVPSell850$41.11$34,943.50View SEC Filing  
11/17/2017Kristen Marie WilliamsCAOSell10,000$40.00$400,000.0023,455View SEC Filing  
11/15/2017David M StackCEOSell58,885$38.34$2,257,650.90159,164View SEC Filing  
11/10/2017Mark A KronenfeldDirectorBuy1,000$41.60$41,600.006,795View SEC Filing  
8/22/2017Paul J HastingsDirectorSell1,044$36.15$37,740.603,518View SEC Filing  
8/15/2017David M StackCEOSell28,885$36.37$1,050,547.45159,164View SEC Filing  
8/15/2017Kristen Marie WilliamsCAOSell3,461$36.75$127,191.7521,312View SEC Filing  
8/8/2017Mark FroimsonDirectorBuy100$37.13$3,713.00100View SEC Filing  
6/5/2017David M StackCEOSell4,311$43.32$186,752.5259,559View SEC Filing  
6/5/2017James S ScibettaPresidentSell1,966$43.32$85,167.1225,118View SEC Filing  
6/5/2017Kristen Marie WilliamsCAOSell1,877$43.32$81,311.6413,773View SEC Filing  
6/5/2017Lauren Bullaro RikerVPSell601$43.32$26,035.32View SEC Filing  
6/5/2017Scott BraunsteinSVPSell768$43.32$33,269.769,982View SEC Filing  
5/15/2017James S ScibettaPresidentSell20,000$51.20$1,024,000.0047,084View SEC Filing  
5/15/2017Kristen Marie WilliamsCAOSell21,041$50.86$1,070,145.2618,775View SEC Filing  
1/17/2017David M. StackCEOSell15,000$38.41$576,150.00View SEC Filing  
1/17/2017James S ScibettaPresidentSell20,000$38.53$770,600.0029,457View SEC Filing  
8/15/2016David M. StackCEOSell15,000$45.32$679,800.00View SEC Filing  
8/15/2016James S. ScibettaPresidentSell25,000$45.21$1,130,250.00View SEC Filing  
6/7/2016Lauren Bullaro RikerVPSell938$47.66$44,705.085,945View SEC Filing  
6/6/2016Kristen Marie WilliamsCAOSell600$47.20$28,320.006,900View SEC Filing  
6/6/2016Lauren Bullaro RikerVPSell321$47.20$15,151.205,945View SEC Filing  
6/6/2016Mark A KronenfeldDirectorSell900$46.95$42,255.002,950View SEC Filing  
4/15/2016David M StackCEOSell25,000$64.14$1,603,500.0025,285View SEC Filing  
1/29/2016Scott BraunsteinSVPBuy2,000$58.92$117,840.002,000View SEC Filing  
1/27/2016James B JonesSVPBuy500$62.50$31,250.001,500View SEC Filing  
1/15/2016David M. StackCEOSell15,000$63.84$957,600.00285View SEC Filing  
1/12/2016James B JonesSVPBuy1,000$66.00$66,000.001,000View SEC Filing  
1/12/2016John P Phd LongeneckerDirectorBuy300$66.55$19,965.002,300View SEC Filing  
10/15/2015David M. StackCEOSell15,000$37.57$563,550.00176View SEC Filing  
9/11/2015James S ScibettaCFOBuy5,000$61.37$306,850.0010,504View SEC Filing  
8/17/2015Paul J HastingsDirectorSell3,000$60.02$180,060.00View SEC Filing  
7/15/2015David M StackCEOSell15,000$67.78$1,016,700.00View SEC Filing  
4/15/2015David M StackCEOSell25,000$90.50$2,262,500.00View SEC Filing  
4/10/2015Paul J HastingsDirectorSell2,500$88.00$220,000.00View SEC Filing  
3/16/2015Lauren Bullaro RikerDirectorSell5,000$95.34$476,700.00View SEC Filing  
3/13/2015Gary W PaceDirectorBuy1,000$93.83$93,830.00View SEC Filing  
2/6/2015James S ScibettaCFOSell15,000$111.22$1,668,300.00View SEC Filing  
1/15/2015David M StackCEOSell15,000$97.52$1,462,800.00View SEC Filing  
1/12/2015Paul J HastingsDirectorSell2,500$94.06$235,150.00View SEC Filing  
12/29/2014John P Phd LongeneckerDirectorSell1,000$93.32$93,320.00View SEC Filing  
12/5/2014Dennis L WingerDirectorBuy2,645$94.54$250,058.30View SEC Filing  
11/7/2014James S ScibettaCFOSell15,000$87.18$1,307,700.00View SEC Filing  
11/7/2014Taunia MarkvickaSVPBuy230$86.62$19,922.60View SEC Filing  
10/10/2014Paul J HastingsDirectorSell2,500$94.87$237,175.00View SEC Filing  
9/29/2014John P Phd LongeneckerDirectorSell1,000$96.40$96,400.00View SEC Filing  
8/29/2014Andreas WickiDirectorSell21,494$108.11$2,323,716.34View SEC Filing  
8/27/2014Andreas WickiDirectorSell55,813$108.08$6,032,269.04View SEC Filing  
8/26/2014Andreas WickiDirectorSell24,207$108.11$2,617,018.77View SEC Filing  
8/25/2014Andreas WickiDirectorSell30,000$108.07$3,242,100.00View SEC Filing  
8/11/2014Andreas WickiDirectorSell150,000$101.25$15,187,500.00View SEC Filing  
8/8/2014James S ScibettaCFOSell15,000$99.63$1,494,450.00View SEC Filing  
8/7/2014Gary PatouInsiderSell20,000$100.26$2,005,200.00View SEC Filing  
7/15/2014David M StackCEOSell15,000$86.75$1,301,250.00View SEC Filing  
7/14/2014Gary PatouInsiderSell29,700$86.96$2,582,712.00View SEC Filing  
7/10/2014Paul J HastingsDirectorSell2,500$84.41$211,025.00View SEC Filing  
6/6/2014Andreas WickiDirectorSell67,900$82.62$5,609,898.00View SEC Filing  
6/3/2014Andreas WickiDirectorSell68,000$80.69$5,486,920.00View SEC Filing  
5/27/2014Andreas WickiDirectorSell64,400$77.93$5,018,692.00View SEC Filing  
5/21/2014Andreas WickiDirectorSell3,600$77.80$280,080.00View SEC Filing  
5/12/2014Gary PatouInsiderSell30,000$74.39$2,231,700.00View SEC Filing  
5/9/2014David StackCEOSell25,000$73.94$1,848,500.001,208View SEC Filing  
5/9/2014Laura BregeDirectorSell10,000$73.85$738,500.00View SEC Filing  
5/8/2014Andreas WickiDirectorSell23,220$75.76$1,759,147.20View SEC Filing  
5/8/2014James ScibettaCFOSell15,000$75.05$1,125,750.005,000View SEC Filing  
5/7/2014Andreas WickiDirectorSell44,780$75.78$3,393,428.40View SEC Filing  
3/28/2014John Phd LongeneckerDirectorSell1,000$64.63$64,630.00View SEC Filing  
3/6/2014Andreas WickiDirectorSell24,887$80.16$1,994,941.92View SEC Filing  
12/30/2013David StackCEOSell15,000$55.84$837,600.002,987View SEC Filing  
12/30/2013James ScibettaCFOSell10,000$55.55$555,500.005,000View SEC Filing  
12/30/2013John Phd LongeneckerDirectorSell2,500$55.55$138,875.00View SEC Filing  
10/1/2013Gary PatouInsiderSell20,000$48.92$978,400.00View SEC Filing  
9/11/2013Andreas WickiDirectorSell17,783$37.25$662,416.75View SEC Filing  
8/14/2013Taunia MarkvickaVPSell14,700$37.00$543,900.00View SEC Filing  
7/22/2013Andreas WickiDirectorSell75,958$35.06$2,663,087.48View SEC Filing  
7/18/2013Andreas WickiDirectorSell25,560$33.45$854,982.00View SEC Filing  
7/16/2013Andreas WickiDirectorSell48,482$33.28$1,613,480.96View SEC Filing  
7/12/2013Taunia MarkvickaVPSell29,754$32.00$952,128.00View SEC Filing  
7/11/2013Andreas WickiDirectorSell80,000$31.48$2,518,400.00View SEC Filing  
7/5/2013Andreas WickiDirectorSell44,021$30.80$1,355,846.80View SEC Filing  
7/3/2013Andreas WickiDirectorSell114,448$30.21$3,457,474.08View SEC Filing  
7/2/2013Gary PatouInsiderSell40,000$29.44$1,177,600.00View SEC Filing  
6/28/2013David M StackCEOSell15,000$28.73$430,950.00View SEC Filing  
6/28/2013James S ScibettaCFOSell10,000$28.05$280,500.00View SEC Filing  
6/28/2013John P Phd LongeneckerDirectorSell2,000$28.09$56,180.00View SEC Filing  
6/24/2013Fred A MiddletonDirectorSell75,900$29.13$2,210,967.00View SEC Filing  
6/20/2013Fred A MiddletonDirectorSell144,100$29.32$4,225,012.00View SEC Filing  
6/19/2013Andreas WickiDirectorSell35,407$29.90$1,058,669.30View SEC Filing  
6/17/2013Andreas WickiDirectorSell50,145$29.86$1,497,329.70View SEC Filing  
6/13/2013John PrattInsiderSell21,032$30.00$630,960.00View SEC Filing  
6/13/2013Luke EvninDirectorSell22,746$30.07$683,972.22View SEC Filing  
6/12/2013Andreas WickiDirectorSell4,409$30.00$132,270.00View SEC Filing  
6/11/2013Andreas WickiDirectorSell11,500$30.00$345,000.00View SEC Filing  
6/11/2013John PrattInsiderSell18,343$30.00$550,290.00View SEC Filing  
6/5/2013Andreas WickiDirectorSell15,500$30.26$469,030.00View SEC Filing  
6/3/2013Andreas WickiDirectorSell1,900$30.00$57,000.00View SEC Filing  
5/31/2013Luke EvninDirectorSell54,517$30.00$1,635,510.00View SEC Filing  
5/29/2013Luke EvninDirectorSell215,528$30.86$6,651,194.08View SEC Filing  
5/22/2013Andreas WickiDirectorSell18,471$30.00$554,130.00View SEC Filing  
5/20/2013Andreas WickiDirectorSell14,374$30.00$431,220.00View SEC Filing  
3/25/2013Andreas WickiDirectorSell290,900$27.95$8,130,655.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pacira Pharmaceuticals (NASDAQ PCRX) News Headlines

Source:
DateHeadline
Pacira Pharmaceuticals (PCRX) Given a $49.00 Price Target at Piper Jaffray CompaniesPacira Pharmaceuticals (PCRX) Given a $49.00 Price Target at Piper Jaffray Companies
www.americanbankingnews.com - February 18 at 10:22 PM
 Analysts Anticipate Pacira Pharmaceuticals Inc (PCRX) Will Post Quarterly Sales of $78.58 Million Analysts Anticipate Pacira Pharmaceuticals Inc (PCRX) Will Post Quarterly Sales of $78.58 Million
www.americanbankingnews.com - February 18 at 4:28 AM
Pacira Pharmaceuticals (PCRX) Rating Reiterated by Canaccord GenuityPacira Pharmaceuticals (PCRX) Rating Reiterated by Canaccord Genuity
www.americanbankingnews.com - February 17 at 3:48 PM
Pacira Pharmaceuticals (PCRX) Downgraded by ValuEnginePacira Pharmaceuticals (PCRX) Downgraded by ValuEngine
www.americanbankingnews.com - February 17 at 1:46 PM
Pacira Pharmaceuticals (PCRX) PT Set at $40.00 by BarclaysPacira Pharmaceuticals (PCRX) PT Set at $40.00 by Barclays
www.americanbankingnews.com - February 17 at 12:42 AM
RSI Alert: Pacira Pharmaceuticals Now OversoldRSI Alert: Pacira Pharmaceuticals Now Oversold
www.nasdaq.com - February 16 at 4:58 PM
This Biotech Stock May Need Anesthesia After Collapsing Nearly 20%This Biotech Stock May Need Anesthesia After Collapsing Nearly 20%
finance.yahoo.com - February 16 at 4:58 PM
Pacira Pharmaceuticals Inc (PCRX) Expected to Announce Earnings of $0.12 Per SharePacira Pharmaceuticals Inc (PCRX) Expected to Announce Earnings of $0.12 Per Share
www.americanbankingnews.com - February 16 at 11:48 AM
Needham & Company LLC Lowers Pacira Pharmaceuticals (PCRX) to HoldNeedham & Company LLC Lowers Pacira Pharmaceuticals (PCRX) to Hold
www.americanbankingnews.com - February 16 at 11:24 AM
Pacira Pharma (PCRX) Confirms Only Four FDA Committee Members Voted to Recommend Approval of EXPAREL sNDAPacira Pharma (PCRX) Confirms Only Four FDA Committee Members Voted to Recommend Approval of EXPAREL sNDA
www.streetinsider.com - February 16 at 8:43 AM
FDA Panel Votes 6-4 Against Recommending This Biotech's Pain BlockerFDA Panel Votes 6-4 Against Recommending This Biotech's Pain Blocker
finance.yahoo.com - February 16 at 8:43 AM
Pacira Pharmaceuticals to Present at the 2018 RBC Capital Markets Healthcare ConferencePacira Pharmaceuticals to Present at the 2018 RBC Capital Markets Healthcare Conference
finance.yahoo.com - February 16 at 8:43 AM
Pacira Pharmaceuticals (PCRX) PT Lowered to $32.00 at BMO Capital MarketsPacira Pharmaceuticals (PCRX) PT Lowered to $32.00 at BMO Capital Markets
www.americanbankingnews.com - February 15 at 8:32 PM
Pacira Pharmaceuticals (PCRX) Stock Rating Reaffirmed by OppenheimerPacira Pharmaceuticals (PCRX) Stock Rating Reaffirmed by Oppenheimer
www.americanbankingnews.com - February 15 at 6:20 PM
Pacira Pharmaceuticals Statement on FDA Advisory Committee for EXPAREL® for Use as a Nerve Block to Produce Regional AnalgesiaPacira Pharmaceuticals Statement on FDA Advisory Committee for EXPAREL® for Use as a Nerve Block to Produce Regional Analgesia
finance.yahoo.com - February 15 at 4:58 PM
Pacira Pharmaceuticals Stock Trading Halted; FDA Advisory ... - NasdaqPacira Pharmaceuticals Stock Trading Halted; FDA Advisory ... - Nasdaq
www.nasdaq.com - February 15 at 8:22 AM
Consolidated Research: 2018 Summary Expectations for Pacira Pharmaceuticals, Wabash National, Spirit Airlines, Praxair, Altice, and Gap — Fundamental Analysis, Key Performance IndicationsConsolidated Research: 2018 Summary Expectations for Pacira Pharmaceuticals, Wabash National, Spirit Airlines, Praxair, Altice, and Gap — Fundamental Analysis, Key Performance Indications
finance.yahoo.com - February 15 at 8:21 AM
What You Must Know About Pacira Pharmaceuticals Inc’s (NASDAQ:PCRX) Financial StrengthWhat You Must Know About Pacira Pharmaceuticals Inc’s (NASDAQ:PCRX) Financial Strength
finance.yahoo.com - February 14 at 5:08 PM
Pacira Pharmaceuticals Stock Trading Halted; FDA Advisory Committee to Review sNDA for EXPAREL® as a Nerve Block for Regional AnalgesiaPacira Pharmaceuticals Stock Trading Halted; FDA Advisory Committee to Review sNDA for EXPAREL® as a Nerve Block for Regional Analgesia
finance.yahoo.com - February 14 at 5:08 PM
Pacira Pharma (PCRX) Confirms FDA EXPAREL Briefing Docs PostedPacira Pharma (PCRX) Confirms FDA EXPAREL Briefing Docs Posted
www.streetinsider.com - February 13 at 9:39 AM
Pacira Pharmaceuticals Inc (PCRX) Given Consensus Recommendation of "Hold" by BrokeragesPacira Pharmaceuticals Inc (PCRX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 13 at 1:38 AM
FDA Posts Briefing Documents for Advisory Meeting Reviewing sNDA for EXPAREL® as a Nerve Block for Regional AnalgesiaFDA Posts Briefing Documents for Advisory Meeting Reviewing sNDA for EXPAREL® as a Nerve Block for Regional Analgesia
finance.yahoo.com - February 12 at 4:06 PM
SCYNEXIS (SCYX) & Pacira Pharmaceuticals (PCRX) Critical ContrastSCYNEXIS (SCYX) & Pacira Pharmaceuticals (PCRX) Critical Contrast
www.americanbankingnews.com - February 11 at 5:12 PM
Implied Volatility Surging for Pacira (PCRX) Stock OptionsImplied Volatility Surging for Pacira (PCRX) Stock Options
finance.yahoo.com - February 9 at 9:34 AM
Pacira Pharmaceuticals Sees Unusually Large Options Volume (PCRX)Pacira Pharmaceuticals Sees Unusually Large Options Volume (PCRX)
www.americanbankingnews.com - February 8 at 1:16 AM
Pacira Pharmaceuticals Target of Unusually High Options Trading (PCRX)Pacira Pharmaceuticals Target of Unusually High Options Trading (PCRX)
www.americanbankingnews.com - February 8 at 1:16 AM
$79.14 Million in Sales Expected for Pacira Pharmaceuticals Inc (PCRX) This Quarter$79.14 Million in Sales Expected for Pacira Pharmaceuticals Inc (PCRX) This Quarter
www.americanbankingnews.com - February 1 at 5:12 AM
Pacira Pharmaceuticals (PCRX) PT Lowered to $42.00Pacira Pharmaceuticals (PCRX) PT Lowered to $42.00
www.americanbankingnews.com - January 30 at 3:20 PM
BidaskClub Lowers Pacira Pharmaceuticals (PCRX) to Strong SellBidaskClub Lowers Pacira Pharmaceuticals (PCRX) to Strong Sell
www.americanbankingnews.com - January 27 at 2:18 PM
FY2017 EPS Estimates for Pacira Pharmaceuticals, Inc. (PCRX) Raised by AnalystFY2017 EPS Estimates for Pacira Pharmaceuticals, Inc. (PCRX) Raised by Analyst
www.americanbankingnews.com - January 24 at 6:30 AM
Seaport Global Securities Initiates Coverage on Pacira Pharmaceuticals (PCRX)Seaport Global Securities Initiates Coverage on Pacira Pharmaceuticals (PCRX)
www.americanbankingnews.com - January 20 at 3:28 PM
Oversold Conditions For Pacira Pharmaceuticals (PCRX)Oversold Conditions For Pacira Pharmaceuticals (PCRX)
www.nasdaq.com - January 19 at 11:51 AM
Pacira Pharmaceuticals, Inc. (PCRX) Receives Average Rating of "Hold" from BrokeragesPacira Pharmaceuticals, Inc. (PCRX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 19 at 1:34 AM
$78.08 Million in Sales Expected for Pacira Pharmaceuticals, Inc. (PCRX) This Quarter$78.08 Million in Sales Expected for Pacira Pharmaceuticals, Inc. (PCRX) This Quarter
www.americanbankingnews.com - January 15 at 11:04 AM
Theravance Biopharma (TBPH) and Pacira Pharmaceuticals (PCRX) Head to Head SurveyTheravance Biopharma (TBPH) and Pacira Pharmaceuticals (PCRX) Head to Head Survey
www.americanbankingnews.com - January 14 at 3:58 AM
Pacira Pharmaceuticals, Inc. (PCRX) CEO David M. Stack Sells 28,885 SharesPacira Pharmaceuticals, Inc. (PCRX) CEO David M. Stack Sells 28,885 Shares
www.americanbankingnews.com - January 12 at 6:26 PM
Pacira Pharmaceuticals (PCRX) Upgraded by ValuEngine to HoldPacira Pharmaceuticals (PCRX) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - January 10 at 11:28 PM
WellStar Health System and Pacira Pharmaceuticals Announce Partnership to Minimize Opioid Use and Standardize Outcomes Across Surgical ProceduresWellStar Health System and Pacira Pharmaceuticals Announce Partnership to Minimize Opioid Use and Standardize Outcomes Across Surgical Procedures
finance.yahoo.com - January 9 at 10:16 AM
WellStar Health System and Pacira Pharmaceuticals Announce Partnership to Minimize Opioid Use and Standardize ... - GlobeNewswire (press release)WellStar Health System and Pacira Pharmaceuticals Announce Partnership to Minimize Opioid Use and Standardize ... - GlobeNewswire (press release)
globenewswire.com - January 8 at 10:32 AM
Pacira Pharmaceuticals (PCRX) Lowered to "Hold" at BidaskClubPacira Pharmaceuticals (PCRX) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - January 6 at 5:06 PM
Pacira Pharmaceuticals (PCRX) Receives Buy Rating from WedbushPacira Pharmaceuticals (PCRX) Receives Buy Rating from Wedbush
www.americanbankingnews.com - January 5 at 8:44 PM
Leerink Swann Comments on Pacira Pharmaceuticals, Inc.s FY2022 Earnings (PCRX)Leerink Swann Comments on Pacira Pharmaceuticals, Inc.'s FY2022 Earnings (PCRX)
www.americanbankingnews.com - January 5 at 8:08 PM
Pacira Pharma (PCRX) Announces Preliminary 2017 Revenues of $286.6M - StreetInsider.comPacira Pharma (PCRX) Announces Preliminary 2017 Revenues of $286.6M - StreetInsider.com
www.streetinsider.com - January 4 at 4:34 PM
Pacira Pharmaceuticals (PCRX) PT Set at $55.00 by HC WainwrightPacira Pharmaceuticals (PCRX) PT Set at $55.00 by HC Wainwright
www.americanbankingnews.com - January 4 at 3:38 PM
Pacira Pharmaceuticals (PCRX) Rating Reiterated by JPMorgan Chase & Co.Pacira Pharmaceuticals (PCRX) Rating Reiterated by JPMorgan Chase & Co.
www.americanbankingnews.com - January 4 at 3:38 PM
Canaccord Genuity Analysts Give Pacira Pharmaceuticals (PCRX) a $46.00 Price TargetCanaccord Genuity Analysts Give Pacira Pharmaceuticals (PCRX) a $46.00 Price Target
www.americanbankingnews.com - January 4 at 12:40 PM
Pacira Pharmaceuticals (PCRX) PT Set at $54.00 by Royal Bank of CanadaPacira Pharmaceuticals (PCRX) PT Set at $54.00 by Royal Bank of Canada
www.americanbankingnews.com - January 4 at 10:28 AM
Pacira Pharmaceuticals Reports Preliminary 2017 Revenues of $286.6 MillionPacira Pharmaceuticals Reports Preliminary 2017 Revenues of $286.6 Million
finance.yahoo.com - January 4 at 10:17 AM
Pacira Pharmaceuticals to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)Pacira Pharmaceuticals to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - January 3 at 4:37 PM
Pacira Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare ConferencePacira Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 9:36 AM

SEC Filings

Pacira Pharmaceuticals (NASDAQ:PCRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pacira Pharmaceuticals (NASDAQ:PCRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pacira Pharmaceuticals (NASDAQ PCRX) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.